Manhattan Pharmaceuticals, Inc. announced tha the first patient has received the initial dose in their Phase 2a clinical study of the company's lead product candidate, topical PTH (1-34) for the treatment of psoriasis

 

Manhattan Pharmaceuticals, U.S. multi-center, randomized, double-blind, vehicle-controlled, parallel group study is designed to evaluate safety and preliminary efficacy of topical PTH (1-34) for the treatment of psoriasis. Approximately 54 subjects will be enrolled and randomized to receive one of two dose levels of topical PTH (1-34), or vehicle, for an 8 week treatment period. In this study the vehicle is the topical formulation without the active ingredient, PTH (1-34). In September 2007, the U.S. Food and Drug Administration (FDA) accepted Manhattan Pharmaceuticals' corporate investigational new drug (IND) application for the company's new formulation of topical PTH (1-34).